Abstract
In the September, 2011, issue of The Lancet Oncology, Savino Di Stasi and colleagues1 report the feasibility and safety of intravesical electromotive drug administration (EMDA) of mitomycin in non-muscle-invasive bladder cancer before transurethral resection of bladder tumours (TURBT). Their results were excellent; they showed that intravesical EDMA before TURBT reduces recurrence rates and enhances the disease-free interval compared with intravesical passive diffusion of mitomycin after TURBT and TURBT alone.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
